|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 9/20 | (2006.01) |
| A61K 9/2866 | (2013.01) | ||
| A61K 31/4162 | (2006.01) | ||
| A61K 31/4162 | (2013.01) | ||
| A61P 3/10 | (2006.01) | ||
| A61K 9/2018 | (2013.01) | ||
| A61K 9/28 | (2006.01) | ||
| A61P 3/10 | (2018.01) |
| (11) | Number of the document | 3038465 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14840833.9 |
| Date of filing the European patent application | 2014-08-25 | |
| (97) | Date of publication of the European application | 2016-07-06 |
| (45) | Date of publication and mention of the grant of the patent | 2021-10-06 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2014/052451 |
| Date | 2014-08-25 |
| (87) | Number | WO 2015/031228 |
| Date | 2015-03-05 |
| (30) | Number | Date | Country code |
| 201361871951 P | 2013-08-30 | US |
| (72) |
COOPER, Vincent, Brett , GB
BRADLEY, Kathryn, Alanna , GB
PYGALL, Samuel, Robert , GB
GUPTA, Rajan , US
STANFORD, Madison, Paige , US
XIE, Lin , US
|
| (73) |
Merck Sharp & Dohme Corp. ,
126 East Lincoln Avenue, Rahway, NJ 07065-0907,
US
Merck Sharp & Dohme Limited , Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, GB |
| (54) | ORAL PHARMACEUTICAL FORMULATION OF OMARIGLIPTIN |
| ORAL PHARMACEUTICAL FORMULATION OF OMARIGLIPTIN |